Approval is for recurrent or advanced mismatch repair deficient (dMMR) endometrial cancer Today, the U.S. Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known … Continue reading FDA Approves Immunotherapy for Endometrial Cancer with Specific Biomarker